Claims for Patent: 6,001,608

Summary for Patent: 6,001,608

Title:	Methods of making an RNP particle having nucleotide integrase activity
Abstract:	Methods for preparing nucleotide integrases are provided. The nucleotide integrases are prepared by combining in vitro an excised, group II intron RNA, referred to hereinafter as \"exogenous RNA\", with a group II intron-encoded protein. The exogenous RNA is prepared by in vitro transcription of a DNA molecule which comprises a group II intron sequence. In one embodiment, the group II intron-encoded protein is made by introducing into a host cell a DNA molecule that comprises at least the open reading frame sequence of a group II intron and then expressing the open reading frame sequence in the host cell. The DNA molecule may comprise the open reading frame sequence operably linked to a promoter, preferably an inducible promoter. Thereafter, the cell is fractionated and the protein is recovered and combined in vitro with the exogenous RNA to provide RNP particles having nucleotide integrase activity. In another embodiment, the DNA molecule comprise a group II intron sequence that encodes both a group II intron RNA as well as a group II intron encoded protein. The DNA molecule is then expressed in the host cell to provide RNP particles that comprise the group II intron-encoded protein bound to the group II intron RNA. Thereafter, the RNP particles comprising the group II intron-encoded protein and the group II intron RNA are isolated from the cell and treated with a nuclease to remove the RNA and to provide the group II-intron encoded protein. The group II intron-encoded protein is then combined in vitro with the exogenous RNA to provide RNP particles having nucleotide integrase activity.
Inventor(s):	Lambowitz; Alan M. (Austin, TX), Mohr; Georg (Austin, TX), Saldanha; Roland (Austin, TX), Matsuura; Manabu (Austin, TX), Beall; Clifford James (Columbus, OH), Yang; Jiam (Dallas, TX), Zimmerly; Steven (Calgary, CA), Guo; Huatao (Austin, TX)
Assignee:	The Ohio State Research Foundation (Columbus, OH)
Application Number:	09/085,603
Patent Claims:	1. A method of preparing RNP particles having nucleotide integrase activity comprising the steps of: (a) providing an isolated, excised group II intron RNA; (b) providing a group II intron-encoded protein; wherein the group II intron-encoded protein is obtained by a process comprising the following steps: (i) introducing a DNA molecule which comprises an open reading frame sequence that encodes said group II intron-encoded protein into a heterologous host cell; (ii) expressing said DNA molecule in said host cell to provide a complex comprising said group II intron-encoded protein bound to an RNA molecule; (iii) isolating said complex from said host cell; and (iv) removing said RNA from said complex to provide said group II intron-encoded protein; and (c) then incubating the excised, group II intron RNA with the group II intron-encoded protein to provide an RNP particle comprising the excised, group II intron RNA bound to the group II intron-encoded protein. 2. The method of claim 1 wherein the DNA molecule lacks an intron sequence upstream of said open reading frame sequence. 3. The method of claim 2 wherein said open reading frame sequence is operably linked to a promoter. 4. The method of claim 1 wherein said complex is obtained from a soluble fraction of the host cell. 5. The method of claim 1 wherein the DNA molecule further comprises a nucleotide sequence encoding a tag for facilitating isolation of the complex. 6. The method of claim 5 wherein the nucleotide sequence which encodes the tag is at the 5' end or the 3' end of the open reading frame sequence. 7. The method of claim 1 wherein the RNA is removed from the complex by contacting the complex with a nuclease. 8. The method of claim 1 wherein the isolated, excised, group II intron RNA is a wild-type group II intron RNA. 9. The method of claim 1 wherein the isolated, excised, group II intron RNA is a modified group II intron RNA. 10. The method of claim 9 wherein the modified group II intron RNA comprises a modification in the loop region of domain IV. 11. The method of claim 9 wherein the modified group II intron RNA has a modified EBS1 sequence. 12. The method of claim 9 wherein the modified group II intron RNA has a modified EBS2 sequence. 13. The method of claim 1 wherein said isolated group II intron RNA comprises a first hybridizing sequence capable of hybridizing with a first intron RNA binding sequence on one strand of a DNA substrate and a second hybridizing sequence capable of hybridizing with a second intron RNA binding sequence on said one strand of the DNA substrate. 14. The method of claim 10 wherein said isolated group II intron RNA further comprises a delta nucleotide that is complementary to a delta prime nucleotide on said one strand of the substrate, said delta prime nucleotide being located at position +1 relative to a cleavage site on said one strand of said DNA substrate. 15. A method of preparing RNP particles having nucleotide integrase activity comprising the steps of: (a) providing an isolated, excised group II intron RNA; (b) providing a group II intron-encoded protein; wherein the group II intron-encoded protein is provided by a process comprising the following steps: (i) introducing a DNA molecule which encodes a wild-type or a modified group II intron RNA into a host cell; (ii) expressing said DNA molecule to provide a complex comprising said group II intron-encoded protein bound to an RNA molecule; (iii) lysing said host cell to provide said complex; (iv) isolating said complex from said host cell; and (v) removing said RNA from said complex to provide said group II-intron encoded protein; and c) then incubating the excised, group II intron RNA with the group II intron-encoded protein to provide an RNP particle comprising the excised, group II intron RNA bound to the group II intron-encoded protein. 16. The method of claim 15 wherein the DNA molecule encodes a splicing-defective group II intron RNA. 17. The method of claim 15 wherein the complex is obtained from a soluble fraction of the lysed cell.

Details for Patent 6,001,608

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-11-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2016-11-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2016-11-19